Profile

Amr R. Hassan, M.D, specializes in Hematology and medical oncology in Burjeel Hospital, Abu Dhabi. Dr. Amr did both his fellowship and residency in The University of Massachusetts Medical School. He is a triple board-certified physician by American Board of Internal Medicine in Internal Medicine, Hematology and Medical Oncology. He has close to 12 years of clinical experience in managing Medical Oncology disorders and Hematologic diseases both benign and malignant.

He has been involved as a principal investigator and a sub-investigator in multiple clinical trials in the USA. He uses the latest treatment regimens and protocols in accordance with the American National Comprehensive Cancer Network (NCCN) guidelines. He has been incorporating the latest approved drugs by the American FDA including targeted chemotherapeutic agents and immunotherapy drugs.

He was most recently the Medical Director of The Cancer Treatment Center at Sky Lakes Medical Center in the USA where he was part of the leadership team in the advancement and the progress of this cancer facility. Dr. Amr did both his fellowship and residency in The University of Massachusetts Medical School. He is a triple board certified by ABIM in Internal Medicine, Hematology and Medical Oncology. Dr. Amr is fluent in English and Arabic.

He was most recently the Medical Director of The Cancer Treatment Center at Sky Lakes Medical Center in the USA where he was part of the leadership team in the advancement and the progress of this cancer facility.

Qualification

• Dr. Amr became a certified Medical Doctor after acquiring his Doctor of Medicine degree from Ross University School of Medicine.
• Bachelor of Science in Biology and Medical Technology from Framingham State University.
• Dr. Amr completed his Residency in Internal Medicine at the University of Massachusetts Memorial Medical Centre, (UMass Medical School).
• Dr. Amr completed his Fellowship in Hematology and Medical Oncology at the University of Massachusetts Memorial Medical Center (UMass Medical School).

Achievements & Certifications

• Board Certificate in Medical Oncology by The American Board of Internal Medicine (ABIM)
• Board Certified in Hematology by The American Board of Internal Medicine (ABIM)
• Board Certified in Internal Medicine by The American Board of Internal Medicine (ABIM)
• Medical Technology certification by The American Society for Clinical Pathology (ASCP)

Research & Publications

• Multi-center, randomized, double-blind phase III trial to evaluate efficiency and safety of B1695502 plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer #2545.
• A randomized phase 3 trial of the efficacy and safety of Glufosfamide compares with 5-FU in patients with metastatic pancreatic adenocarcinoma previously treated with Gemcitabine #2550
• Development of risk- prediction models for chemotherapy-induced febrile neutropenia in patients with breast cancer, colorectal cancer, lung cancer, and non-Hodgkin lymphoma #2554
• Prospective, non-interventional study of disease progression and treatment of patients with polycythemia vera in the United States academic and community clinical practices (REAVEL) #2555
• A prospective observational cohort study of patients with castration-resistant prostate adenocarcinoma (CRPC) in the United States #2562
• An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with active P13K pathway #2533
• A randomized, double-blind, parallel-group, multi-center, phase 3 trial to compare the efficacy and tolerability of Fulvestrant (Faslodex) 500 mg with Anastrazole (Arimidex) 1 mg as hormonal treatment for postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy (FALCON) #2519
• A phase 3, randomized, double-blind, active comparator-controlled parallel-group study, conducted under in-house blinding conditions to examine the efficacy and safety of a single 150 mg dose of intravenous Fosaprepitant Digmeglumine for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy #2523
• A phase lb./2 study of Docetaxel with or without Buparlisib as second line therapy for patients with advanced or metastatic squamous non-small cell lung cancer #2534
• A multi-center, randomized, double-blind, placebo-controlled phase 3 trial of Tecemotide vs placebo in patient with completed concurrent chemo-radiotherapy for unresectable stage 3 non-small cell lung cancer (NSCLC) #2540
• A phase 2, non-comparative, open label, multi-center international study of MEDI4736 in patients with locally advanced or metastatic non-small cell lung cancer (stage 3B-4) who have received at least two prior systemic treatment regiments including one Platinum-based chemotherapy regimen (ATLANTIC) #2543
• Safety and efficacy of Nab-Palitaxel (Abraxane) in combination with Carboplatin as first line treatment in elder patients with advanced non-small cell lung cancer (NSCLC): A phase 4, randomized, open label, multi-center study #2553
• MIST: MEDI4736 historic control arm of 3rd line non-small cell lung cancer patients, a retrospective cohort study #2563
• A phase 3 randomized study to assess the efficacy and safety of Ublituximab in combination with lbrutinib compared to Inrutinib alone in patients with previously treated high-risk chronic lymphocytic leukemia (CLL) #2565.
• Safety of radiofrequency ablation (RFA) of liver metastasis secondary to colorectal adenocarcinoma in patients treated with Avastin and 5-FU based therapy poster presentation in June 2007.
• Coronary vasospasm with myocardial stunting in-patient with colon adenocarcinoma receiving adjuvant chemotherapy with FOLFOX regimen.

Professional & Memberships

• American Society of Clinical Oncologist (ASCO)
• American College of Physicians (ACP)
• American Society of Clinical Pathologists (ASCP)

Language Spoken: English and Arabic